Our observation of systemic metabolic disturbances in Mybpc3−/− mice due to cardiac hypertrophy may help identify new biomarkers or therapeutic targets that address not only the heart but also the systemic metabolic consequences of cardiac dysfunction. Here, MYBPC3 is linked to cardiac hypertrophy.